Skip to content

Influence of Deep Versus Moderate Neuromuscular Blockade During General Anesthesia on 30-day Readmission Rates

Influence of Deep Versus Moderate Neuromuscular Blockade During General Anesthesia on 30-day Readmission Rates: A Retrospective Analysis of Patient Chart Data

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03174223
Enrollment
460
Registered
2017-06-02
Start date
2017-06-01
Completion date
2018-07-01
Last updated
2019-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Complications, Postoperative Wound Infection, Pneumonia

Brief summary

Deep neuromuscular block (NMB) has shown to produce superior surgical conditions during various abdominal and non abdominal surgeries. It is however unknown if the application of deep NMB leads to favourable outcome, such as lower rate of postoperative complications in general and surgical infections in specific and ultimately lower readmission rates. In the leiden university medical center, deep NMB is routinely applied for a variety of procedures, most notably laparoscopic abdominal and retroperitoneal surgery, eye surgery and neuro radiologic intervention surgery, since 2014. This retrospective study intends to investigate whether the application of deep NMB for these procedures affects patient outcome and readmission rates.

Interventions

a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count

Sponsors

Merck Sharp & Dohme LLC
CollaboratorINDUSTRY
Leiden University Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* deep neuromuscular block * moderate neuromuscular block * general anesthesia * complete anesthesia chart

Exclusion criteria

* incomplete anesthesia chart * missing data regarding postoperative complications or readmission

Design outcomes

Primary

MeasureTime frameDescription
Readmission30 days after surgeryreadmission to the hospital

Secondary

MeasureTime frameDescription
Cost30 days after surgeryThe total cost, including sugammadex use and readmission cost

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026